LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage

References

• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
   PubMed Web of Science ®Google Scholar
• Bergin K, McQuilten Z, Moore E, et al. Myeloma in the real world: what is really happening? Clin Lymphoma Myeloma Leuk. 2017;17:133–144 e1.
   PubMed Web of Science ®Google Scholar
• Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26:2737–2744.
   PubMed Web of Science ®Google Scholar
• Dutta AK, Hewett DR, Fink JL, et al. Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. Br J Haematol. 2017;178:196–208.
   PubMed Web of Science ®Google Scholar
• Joao C, Costa C, Coelho I, et al. Long-term survival in multiple myeloma. Clin Case Rep. 2014;2:173–179.
   PubMedGoogle Scholar
• Neparidze N, Lacy J. Malignancies associated with Epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clin Adv Hematol Oncol. 2014;12:358–371.
   PubMedGoogle Scholar
• Mameli G, Fozza C, Niegowska M, et al. Epstein–Barr virus infection is associated to patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Leuk Lymphoma. 2017;58:466–469.
   PubMed Web of Science ®Google Scholar
• Horikawa T, Yoshizaki T, Kondo S, et al. Epstein-Barr virus latent membrane protein 1 induces snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma. Br J Cancer. 2011;104:1160–1167.
   PubMed Web of Science ®Google Scholar
• Wang LW, Jiang S, Gewurz BE. Epstein-Barr virus LMP1 mediated oncogenicity. J Virol. 2017;91:pii: e01718–pii: e01716.
   Web of Science ®Google Scholar
• Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757–768.
   PubMed Web of Science ®Google Scholar
• Chen YP, Zhang WN, Chen L, et al. Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis. Oncotarget. 2015;6:29311–29323.
   PubMedGoogle Scholar
• Yan J, Wang J, Zhang W, et al. Solitary plasmacytoma associated with Epstein-Barr virus: a clinicopathologic, cytogenetic study and literature review. Ann Diagn Pathol. 2017;27:1–6.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645.
   PubMed Web of Science ®Google Scholar
• Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol. 2013;163:551–564.
   PubMed Web of Science ®Google Scholar
• Yaccoby S. Two states of myeloma stem cells. Clin Lymphoma Myeloma Leuk. 2018;18:38–43.
   PubMed Web of Science ®Google Scholar
• Gao M, Kong Y, Yang G, et al. Multiple myeloma cancer stem cells. Oncotarget. 2016;7:35466–35477.
   PubMedGoogle Scholar
• Foster BM, Zaidi D, Young TR, et al. CD117/c-kit in cancer stem cell-mediated progression and therapeutic resistance. Biomedicines. 2018;6:31.
   PubMed Web of Science ®Google Scholar
• Zhou W, Yang Y, Gu Z, et al. ALDH1 activity identifies tumor initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 2014;28:1155–1158.
   PubMed Web of Science ®Google Scholar
• Morris MA, Laverick L, Wei W, et al. The EBV-encoded oncoprotein, LMP1, induces an epithelial-to-mesenchymal transition (EMT) via its CTAR1 domain through integrin-mediated ERK-MAPK signalling. Cancers. 2018;10:pii: E130.
   Web of Science ®Google Scholar
• Kondo S, Wakisaka N, Muramatsu M, et al. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J Virol. 2011;85:11255–11264.
   PubMed Web of Science ®Google Scholar
• Association WM. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387–391.
   PubMed Web of Science ®Google Scholar
• Woodward WA, Krishnamurthy S, Lodhi A, et al. Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with the presence of circulating or disseminated tumors cells. J Cancer. 2014;5:360.
   PubMed Web of Science ®Google Scholar
• Zhao F, Chen Y, Wu Q, et al. Prognostic value of CD117 in cancer: a meta-analysis. Int J Clin Exp Pathol. 2014;7:1012–1021.
   PubMed Web of Science ®Google Scholar
• Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002;117:259–267.
   PubMed Web of Science ®Google Scholar
• Rickinson A. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Strauss SE, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2575–2627.
   Google Scholar
• Chang ST, Liao YL, Lu CL, et al. Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol. 2007;128:339–344.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Ivan C, Ciccone M, et al. Epstein–Barr virus microRNAs are expressed in patients with chronic lymphocytic leukemia and correlate with overall survival. EBioMedicine. 2015;2:572–582.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118:6018–6022.
   PubMed Web of Science ®Google Scholar
• Marques H, Catarino R, Domingues N, et al. Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkin’s lymphoma is not associated with prognosis. Oncol Lett. 2012;4:1285–1289.
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Hegde AM, Durand CM, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127:2007–2017.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng X, Chen B, et al. The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2017;58:2349–2355.
   PubMed Web of Science ®Google Scholar
• Min BH, Tae CH, Ahn SM, et al. Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma. Gastric Cancer. 2016;19:852–859.
   PubMed Web of Science ®Google Scholar
• Loghavi S, Alayed K, Aladily TN, et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015;8:65.
   PubMed Web of Science ®Google Scholar
• Long X, Li Y, Yang M, et al. BZLF1 attenuates transmission of inflammatory paracrine senescence in Epstein-Barr virus-infected cells by downregulating TNFα. J Virol. 2016;90:7880–7893.
   PubMed Web of Science ®Google Scholar
• Nanbo A, Katano H, Kataoka M, et al. Infection of Epstein-Barr virus in type III latency modulates biogenesis of exosomes and the expression profile of exosomal miRNAs in the burkitt lymphoma mutu cell lines. Cancers. 2018;10:237.
   Web of Science ®Google Scholar
• He B, Li W, Wu Y, et al. Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell metastasis and invasion by targeting long non-coding RNA LOC553103. Cell Death Dis. 2016;7:e2353.
   PubMed Web of Science ®Google Scholar